# How Regeneron makes money

CXProWealth Business Lens · Regeneron (REGN) · Q3 FY2026

Read from the 10-Q for the period 2026-07-01 to 2026-09-30, filed 2026-10-30 with the SEC (accession 0000872589-26-000034): https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/

Business Lens explains how a company earns, spends and keeps its money, from its own filings. It is insight and context, never a view on the shares, a target, or advice. Figures are raw units as filed; percentages are percentage points.

## Headline figures

- Revenue: $5.1B (+68.9% on the year)
- Operating income: $2.0B (operating margin 40.0%)
- Net income: $1.9B (net margin 38.1%)
- Gross margin: not reported (the company reports expenses by nature: no cost of revenue or gross profit line exists)
- Free cash flow: $1.5B (29.0% of revenue)
- Cash conversion (operating cash flow / net income): 0.92x
- Capital expenditure: 5.9% of revenue

## Where the money goes (Q3 FY2026)

- Net product sales → Revenues: $1.8B
- Collaboration revenue → Revenues: $3.0B
- Other revenue → Revenues: $310.0M
- Revenues → Total Expenses: $3.1B
- Total Expenses → Research and development: $1.8B
- Total Expenses → Acquired in-process research and development: $21.5M
- Total Expenses → Selling, general, and administrative: $677.8M
- Total Expenses → Cost of goods and services sold: $573.6M
- Revenues → Income from operations: $2.0B
- Income from operations → Income before income taxes: $2.0B
- Total other income (expense) → Income before income taxes: $235.9M
- Income before income taxes → Income tax expense: $335.4M
- Income before income taxes → Net income: $1.9B

## Where the revenue comes from

### Products and services (CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited))

| Member | Value | Share |
|---|---:|---:|
| Collaboration revenue | $3.0B | 58.7% |
| Net product sales | $1.8B | 35.3% |
| Other revenue | $310.0M | 6.1% |

The members sum to total revenue.

## Income statement, as filed

| Line | Q3 FY2026 | Of revenue |
|---|---:|---:|
| Revenues | $5.1B | 100% |
|   Net product sales | $1.8B | 35.3% |
|   Collaboration revenue | $3.0B | 58.7% |
|   Other revenue | $310.0M | 6.1% |
| Research and development | $1.8B | 35.1% |
| Acquired in-process research and development | $21.5M | 0.4% |
| Selling, general, and administrative | $677.8M | 13.2% |
| Net product sales | $321.7M | 6.3% |
| Cost of collaboration and contract manufacturing | $251.9M | 4.9% |
| Other operating (income) expense, net | ($0) | 0.0% |
| **Total Expenses** | $3.1B | 60.0% |
| **Income from operations** | $2.0B | 40.0% |
| Other income (expense), net | $246.5M | 4.8% |
| Interest expense | ($10.6M) | 0.2% |
| **Total other income (expense)** | $235.9M | 4.6% |
| **Income before income taxes** | $2.3B | 44.6% |
| Income tax expense | $335.4M | 6.6% |
| **Net income** | $1.9B | 38.1% |
| Net income per share - basic (in dollars per share) | $19 | 0.0% |
| Net income per share - diluted (in dollars per share) | $18 | 0.0% |
| Weighted average shares outstanding - basic (in shares) | 101,700,000 |  |
| Weighted average shares outstanding - diluted (in shares) | 105,600,000 |  |
| **Net income** | $1.9B | 38.1% |
| Unrealized (loss) gain on debt securities | -$160.8M | 3.1% |
| (Loss) gain on foreign currency translation | -$900.0K | 0.0% |
| **Comprehensive income** | $1.8B | 34.9% |

## History

| Period | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---:|---:|---:|---:|---:|---:|
| FY2008 | $238.5M | -$86.2M | -$79.1M | -$89.1M | $34.9M | -$123.9M |
| FY2009 | $379.3M | -$74.1M | -$67.8M | -$69.9M | $97.3M | -$167.3M |
| FY2010 | $459.1M | -$97.5M | -$104.5M | $99.2M | $99.7M | -$467.0K |
| FY2011 | $445.8M | -$205.2M | -$221.8M | -$141.7M | $57.2M | -$198.9M |
| FY2012 | $1.4B | $457.7M | $750.3M | -$74.6M | $49.3M | -$124.0M |
| FY2013 | $2.1B | $743.1M | $413.7M | $588.6M | $156.3M | $432.3M |
| FY2014 | $2.8B | $823.9M | $338.1M | $752.4M | $333.0M | $419.4M |
| FY2015 | $4.1B | $1.3B | $636.1M | $1.3B | $677.9M | $652.8M |
| FY2016 | $4.9B | $1.3B | $895.5M | $1.5B | $511.9M | $974.0M |
| FY2017 | $5.9B | $2.1B | $1.2B | $1.3B | $272.6M | $1.0B |
| FY2018 | $5.1B | $2.5B | $2.4B | $2.2B | $383.1M | $1.8B |
| FY2019 | $6.6B | $2.2B | $2.1B | $2.4B | $429.6M | $2.0B |
| FY2020 | $8.5B | $3.6B | $3.5B | $2.6B | $614.6M | $2.0B |
| FY2021 | $16.1B | $8.9B | $8.1B | $7.1B | $551.9M | $6.5B |
| FY2022 | $12.2B | $4.7B | $4.3B | $5.0B | $590.1M | $4.4B |
| FY2023 | $13.1B | $4.0B | $4.0B | $4.6B | $718.6M | $3.9B |
| FY2024 | $14.2B | $4.0B | $4.4B | $4.4B | $755.9M | $3.7B |
| FY2025 | $14.3B | $3.6B | $4.5B | $5.0B | $898.4M | $4.1B |

Latest trend (the newest full year against the year before; a reading, not a forecast):

- Revenue: +1.0% (year before +8.3%): slowing
- Operating income: -10.3% (year before -1.4%): slowing
- Net income: +2.1% (year before +11.6%): slowing
- Free cash flow: +11.3% (year before -5.4%): accelerating

## Operating figures stated in the filing

- Largest customer (Customer A) share of gross product revenue: 48.0% (as of 2026-09-30). "Customer A 48 % 49 % 46 % 51 %" (Item 1. Financial Statements)
- Largest customer (Customer A) share of gross product revenue: 49.0% (as of 2025-09-30). "Customer A 48 % 49 % 46 % 51 %" (Item 1. Financial Statements)
- Second customer (Customer B) share of gross product revenue: 30.0% (as of 2026-09-30). "Customer B 30 % 30 % 31 % 26 %" (Item 1. Financial Statements)
- Second customer (Customer B) share of gross product revenue: 30.0% (as of 2025-09-30). "Customer B 30 % 30 % 31 % 26 %" (Item 1. Financial Statements)

## Key insights

### Partner profit shares now outweigh Regeneron's own sales

Collaboration revenue rose 52.4% to $3.0B, 58.7% of revenue against 35.3% for net product sales, as Dupixent grew and the Sanofi repayment deductions ended.

Collaboration revenue was $3.0B against $1.97B a year earlier, 58.7% of the quarter's $5.1B revenue and 6.2 points more of the total. Net product sales, the medicines Regeneron sells itself, rose 13.7% to $1.8B and fell 7.0 points to 35.3% of revenue. Most of the collaboration line is Regeneron's share of profits on Dupixent and Kevzara, sales that Sanofi records as its own. _(from the filing)_
The filing names two causes: higher Dupixent sales, and "the full repayment of the Sanofi development balance" by the end of the second quarter. That balance was Regeneron's obligation to repay development costs Sanofi had funded, deducted from its profit share until cleared. With it gone, the full share reaches revenue. Bayer collaboration revenue moved the other way, with lower EYLEA sales outside the US. _(from the filing)_
Part of the jump is a one-time step rather than a trend. Once the quarters after the repayment are lapped, growth in this line rests on Dupixent's own sales. The larger point is structural: most of Regeneron's revenue is now its cut of a product whose sales sit on another company's income statement. _(analysis)_

### Operating income nearly doubled while costs rose 12.5%

Operating income rose 99.5% to $2.05B, 57.2% of last year's full-year operating income, because most added revenue arrived without matching cost.

Total expenses rose 12.5% to $3.07B against revenue growth of 36.3%, so operating income climbed to $2.05B from $1.03B and operating margin widened 12.7 points to 40.0%. This one quarter's operating income equals 57.2% of the $3.58B the company earned from operations in all of the last full year. _(from the filing)_
Research and development rose to $1.79B from $1.48B, yet fell to 35.1% of revenue from 39.3%. Selling, general and administrative cost was nearly flat at $677.8M against $657.8M, falling to 13.2% of revenue from 17.5%. The filing records Sanofi's reimbursement of shared commercial costs as a reduction of that line. _(from the filing)_
The leverage comes from where the new revenue arrived. A profit share is booked after the partner's own selling costs, so when it grows, little new expense follows it onto Regeneron's statement. That makes the margin sensitive to the same things as the revenue: Dupixent's sales and the terms of the Sanofi agreement. _(analysis)_

### Earnings now come from operations, not portfolio gains

A year ago net income was 142.2% of operating income, lifted by securities gains; this quarter it is 95.1%.

Total other income fell 68.0% to $235.9M from $736.5M, and the filing's breakdown attributes the drop to smaller gains on marketable and other securities. A year ago other income equalled 71.7% of operating income; this quarter it was 11.5%. Net income therefore rose 33.5% to $1.95B, far less than operating income's 99.5% rise, and net margin slipped 0.8 points to 38.1%. _(from the filing)_
The same pattern ran through the last full year, when net income of $4.50B was 125.9% of operating income of $3.58B. This quarter the effective tax rate eased to 14.7% from 17.2%, and unrealized losses of $160.8M on debt securities pulled comprehensive income to $1.79B, below net income. _(from the filing)_
Operating income is the cleaner read of the business, and it is now carrying the result rather than the investment book. The gap between the two lines still depends on markets the company does not control, so a strong securities quarter can again lift net income above what operations earned. _(analysis)_

### Competitive edge

- **One antibody engine feeds every product line** Research and development of $1.79B is 35.1% of revenue against 13.2% for selling, general and administrative cost, the spending profile of an inventor rather than a seller.
- **Partners supply the global sales force** Sanofi and Bayer sell much of Regeneron's portfolio abroad, so selling, general and administrative cost fell to 13.2% of revenue from 17.5%.
- **EYLEA HD moves patients before copies arrive** Regeneron is shifting patients to a higher-dose version that copies of the original do not replicate, and HD volumes are rising.

### What to watch

- **Three medicines carry most of the business** The filing calls Regeneron substantially dependent on EYLEA HD, EYLEA and Dupixent, while EYLEA faces launched biosimilars and patent challenges.
- **A partner books the product that drives growth** Collaboration revenue is 58.7% of revenue, and Sanofi, not Regeneron, records Dupixent sales and leads its payor negotiations.
- **Government pricing deals point to lower prices** The filing says agreements with the US government will likely reduce prices for certain products, and its tariff exemption depends on US investment.

## Investor view

**Collaboration revenue, led by Regeneron's share of Dupixent profits, rose 52.4% and now outweighs its own product sales**

### How it makes money

Regeneron earns from three lines. Collaboration revenue of $3.0B was 58.7% of the quarter's $5.1B revenue, net product sales of $1.8B were 35.3%, and other revenue of $310.0M was 6.1%. The largest piece is its share of profits on Dupixent and Kevzara, which Sanofi records as its own sales. The two split US profits equally and share profits outside the US on a sliding scale that moves toward Regeneron as sales grow. _(from the filing)_
Net product sales are the medicines Regeneron sells itself: EYLEA HD and EYLEA in the US, Libtayo worldwide, and Praluent and Evkeeza in the US. It sells to distributors and specialty pharmacies, and the buyers are concentrated: the largest took 48% of gross product revenue in the quarter and the second 30%, against 49% and 30% a year earlier. _(from the filing)_
Outside the US, Bayer sells EYLEA HD and EYLEA and the two share those profits equally, which shows up as collaboration revenue rather than product sales. Other revenue of $310.0M, up from $198.2M a year earlier, is royalties and profit shares from licensed products, such as royalties on Novartis' Ilaris and a share of Kiniksa's ARCALYST profits, plus manufacturing done for others. _(from the filing)_
The company reports costs by type, so there is no gross profit line. Research and development of $1.79B was 58.5% of total expenses of $3.07B and 35.1% of revenue. Selling, general and administrative cost was $677.8M, reported after Sanofi's reimbursement of shared commercial expenses, which the filing records as a reduction of that line. What remained was operating income of $2.05B, a 40.0% operating margin. _(from the filing)_
Read together, the lines describe an inventor and manufacturer that rents much of its reach. Regeneron owns discovery, clinical development and bulk production; partners own most of the selling, pricing and payor negotiation outside the US, and Sanofi books Dupixent everywhere. Reported revenue is a mix of its own sales and its cut of far larger sales recorded by Sanofi and Bayer, so its results track products whose top line sits on another company's income statement. _(analysis)_

### What shifted

Revenue rose 36.3% to $5.1B from $3.75B a year earlier, and most of the increase came from collaboration revenue, up 52.4% to $3.0B from $1.97B. Its share of revenue rose 6.2 points to 58.7%. The filing names two causes: higher Dupixent sales, and "the full repayment of the Sanofi development balance", which ended the deductions Regeneron had been making from its profit share to repay development costs Sanofi had funded. _(from the filing)_
Costs grew far more slowly than revenue. Total expenses rose 12.5% to $3.07B, so operating income nearly doubled, up 99.5% to $2.05B from $1.03B, and operating margin widened 12.7 points to 40.0%. Research and development rose to $1.79B from $1.48B, yet fell to 35.1% of revenue from 39.3%. Selling, general and administrative cost was nearly flat at $677.8M against $657.8M, falling to 13.2% of revenue from 17.5%. _(from the filing)_
Below operating income, the year-earlier quarter had help that this one lacked. Total other income fell 68.0% to $235.9M from $736.5M, and the filing's breakdown shows the drop came from smaller gains on marketable and other securities. Net income therefore rose less than operating income, up 33.5% to $1.95B from $1.46B, and net margin slipped 0.8 points to 38.1%. The effective tax rate eased to 14.7% from 17.2%. _(from the filing)_
Regeneron's own product sales grew more slowly, up 13.7% to $1.8B, so their share of revenue fell 7.0 points to 35.3%. The filing says EYLEA HD rose on "higher sales volumes, partly offset by a lower net selling price", while EYLEA fell on "continued competitive pressures" and the move of patients to EYLEA HD. Libtayo grew on volume. Bayer collaboration revenue fell with lower EYLEA sales outside the US. _(from the filing)_
Per share results rose faster than net income because there were fewer shares. Diluted earnings per share were $18.45 against $13.62 a year earlier, on 105.6M diluted shares against 107.2M, after continued buybacks. Cash kept pace with profit: free cash flow was $1.48B, a 29.0% margin on revenue, after capital spending equal to 5.9% of revenue. _(from the filing)_

### Risks in the filing

The company says it is "substantially dependent" on EYLEA HD, EYLEA and Dupixent. EYLEA's US regulatory exclusivity has expired, several biosimilars are approved and some have launched, more are expected, and competition abroad will grow as copies reach more countries, which cuts into what Regeneron earns from Bayer. Patents covering EYLEA and EYLEA HD are under challenge in the US and Europe. _(from the filing)_
Prices and coverage can move against it. Payors and pharmacy benefit managers demand rebates, prior authorization and step therapy; the Inflation Reduction Act lets Medicare set prices for selected drugs; and the filing says its agreements with the US government will likely reduce prices for certain products. Its exemption from tariffs under the Commerce Department's investigation depends on keeping its commitments to invest in US manufacturing and research. _(from the filing)_
Regeneron relies on Sanofi and Bayer to sell some of its largest products and has limited commercial capability outside the US. Bayer can end its agreement on advance notice, and losing either partner would leave the company to build or buy sales capacity abroad. Sanofi records Dupixent sales and leads payor negotiations, so Regeneron depends on its execution. _(from the filing)_
Supply and legal exposure are concentrated. The company names limited internal and contract manufacturing capacity and its plants in Rensselaer, New York and Limerick, Ireland as points of failure; a repair at Limerick earlier in the year interrupted bulk production and left unabsorbed costs, though product supply was not affected. It also faces Justice Department cases over patient assistance and pricing reports, and product liability suits claiming Dupixent caused or worsened T-cell lymphoma. _(from the filing)_
Two of these risks already show in the quarter. Dependence on Sanofi deepened as collaboration revenue gained share against Regeneron's own sales, and EYLEA erosion shows in a product line that grew far more slowly than revenue. Pricing pressure is visible only at the edge, in a lower net price for EYLEA HD; the full effect of the government agreements and Medicare negotiation is not yet visible in these lines. _(analysis)_

## Founder view: mechanisms

### Partner sells, inventor shares the profit

Regeneron discovers and makes the antibody; Sanofi records global sales of Dupixent and Kevzara, leads payor negotiations and most commercial work abroad, and pays Regeneron a share of the profit. Regeneron keeps a right to co-commercialize and is reimbursed for shared commercial costs. It gets a global field force without building one, and pays for it with part of the margin and with control over pricing and the customer relationship. _(analysis)_

### Partner funds development, repaid from profits

Sanofi paid development costs up front and Regeneron repaid its share out of its share of profits; Bayer has a similar obligation, capped at Regeneron's quarterly profit share. The partner acts as a lender repaid only when there are profits. Once the balance is cleared, the full profit share flows to revenue. The Sanofi balance was fully repaid by the end of the second quarter, and that is part of this quarter's step-up. _(analysis)_

### One discovery engine, many products

Regeneron's core is a set of in-house technologies, VelocImmune and the wider VelociSuite, that generate fully human antibodies repeatedly. Products in eye disease, immunology, cancer, cardiovascular disease and rare disease come out of the same engine, and those discoveries are what it brings to partners. Research and development is the main use of its income. _(analysis)_

### Replace your own product before a copy does

EYLEA's US exclusivity has ended and biosimilars are launching. Regeneron launched EYLEA HD, a higher-dose version that allows longer gaps between injections, and is moving patients to it while adding indications, longer dosing intervals and a pre-filled syringe. Part of the old product's decline is by design: a patient moved to HD is one a cheaper copy of the original cannot win on price alone. _(analysis)_

## Member research

Signed-in members read, on the page: what Regeneron's numbers depend on from here, and the playbook behind each mechanism (what needs scale, what transfers, how to test it, the metric that would show it).

## Sources

- Regeneron 10-Q for the period to 2026-09-30: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/ (2026-10-30)

Methodology business-lens-1.0 · schema 1.2.0 · run business-lens-2026-11-02 · as of 2026-11-02